Skip to main content
Clinical Trials/JPRN-UMIN000043918
JPRN-UMIN000043918
Completed
N/A

A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102) - A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102)

Iwakuni Clinical Center0 sites500 target enrollmentApril 14, 2021
Conditionsung cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
ung cancer
Sponsor
Iwakuni Clinical Center
Enrollment
500
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 14, 2021
End Date
October 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Iwakuni Clinical Center

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with a history of developing COVID\-19 2\) Patients with a history of SARS\-CoV\-2 vaccination 3\) Patients who think that it is inappropriate for their doctor to inoculate SARS\-CoV\-2 vaccine 4\) Patients with an estimated prognosis within 2 months

Outcomes

Primary Outcomes

Not specified

Similar Trials